✦ LIBER ✦

Imidazoline I1 receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease

✍ Scribed by Mitsuo Tanabe; Masako Hashimoto; Hideki Ono

Book ID: 113587693
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 602 KB
Volume: 589
Category: Article
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2008.06.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Striatal Cannabinoid CB1 Receptor mRNA E

Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease

✍ M.A. Silverdale; S. McGuire; A. McInnes; A.R. Crossman; J.M. Brotchie 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 145 KB

The Cannabinoid Receptor Agonist WIN 55,

The Cannabinoid Receptor Agonist WIN 55,212-2 Reduces D2, but Not D1, Dopamine Receptor-Mediated Alleviation of Akinesia in the Reserpine-Treated Rat Model of Parkinson's Disease

✍ Y.P. Maneuf; A.R. Crossman; J.M. Brotchie 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 88 KB

Effects of CB1 cannabinoid receptor modu

Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease

✍ Gregorio Segovia; Francisco Mora; Alan R. Crossman; Jonathan M. Brotchie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract The present study was designed to determine the potential of CB1 cannabinoid receptor modulating compounds in the treatment of L‐3,4‐dihydroxyphenylalanine (L‐dopa)–induced dyskinesia in Parkinson's disease. In the reserpine‐treated rat model of parkinsonism, administration of a high do

Ginsenoside Rg1 protects dopaminergic ne

Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway

✍ Li Xu; Wen-Fang Chen; Man-Sau Wong 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 692 KB